natgillin/translations-raw huggingface dataset:
A further advantageous application of the formulations of the invention is their use during preparation for surgical operations on the large intestine, in ileocolic anastomoses, and in the sterilization of the ammonia-producing colonic flora in order to prevent and/or treat hyperammonaemias. 
Daljnja prednost primjene pripravaka ovog izuma jest njihova upotreba tijekom priprema za kirurške operacije debelog crijeva, pri ileokoličnim anastomozama, u sterilizaciji flore kolona koja proizvodi amonijak s ciljem sprečavanja i/ili liječenja hiperamonemija.
An antibody of any one of claims 1 to 14 and/or a conjugate of claim 16 for use in a method of inhibiting growth and/or killing of a cell expressing CLD 18. 
Protutijelo sukladno patentnom zahtjevu 1 i/ili konjugat sukladno patentnom zahtjevu 3 za uporabu u postupku za inhibiciju rasta i/ili uništavanje stanice koja eksprimira CLD18A2.
The immunogenic composition of any one of paragraphs 45-59 comprising a Hib saccharide conjugate and at least two further bacterial saccharide conjugates wherein the Hib conjugate is present in a lower dose than the mean dose of the at least two further bacterial saccharide conjugates. 
Imunogeni pripravak, naznačen time što sadrži konjugat saharida Hib i najmanje dva dodatna konjugata bakterijskih saharida, gdje konjugat Hib je prisutan u manjoj dozi saharida od srednje doze saharida za sve od najmanje dva dodatna konjugata bakterijskih saharida.
The method of claim 14, 15 or 16, wherein the recombinant adeno-associated viral (rAAV) vector is selected from the group consisting of an AAV serotype 1, an AAV serotype 2, an AAV serotype 3, an AAV serotype 4, an AAV serotype 5 and an AAV serotype 6. 
Postupak prema zahtjevu 14, 15 ili 16, naznačen time da je rekombinantni adeno-povezani virusni (rAAV) vektor odabran iz skupine koju čine AAV serotip 1, AAV serotip 2, AAV serotip 3, AAV serotip 4, AAV serotip 5 i AAV serotip 6.
R12, at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R10a; R14, at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; and 
, svaki put kada je prisutan, je nezavisno izabran između vodika, alkil, alkenil, alkinil, cikloalkil, aril, arilalkil, heterociklil i heterociklilalkil, gdje cikloalkil, aril, arilalkil, heterociklil i heterociklilalkil može svaki biti po izboru supstituiran s 0-3 R10a;, svaki put kada je prisutan, je nezavisno izabran između vodika, alkil, cikloalkil i aril; i
The compounds may also be used in combination with bisphosphonates and other agents for the treatment and/or prevention of disturbances of calcium, phosphate and bone metabolism, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with a GnRH antagonist. 
Spojeve se također može upotrijebiti u kombinaciji s bisfosfonatima 1 drugim sredstvima za liječenje iili sprječavanje poremećaja metabolizma kalcija, fosfata i kostiju, te u kombinaciji s estrogenima, progesteronima i/ili androgenima za sprječavanje ili liječenje gubitka koštane mase ili simptoma hipogonadizma, poput napadaja vrućine tijekom terapije antagonistom GnRH.
where the said net-like structure or semi-permeable membranes (2) forms the connecting channel structures for air circulation and forced cooling via air stream from the nozzles (19) situated into said structures, and 
- > gdje rečeni mrežasti ili membranski spojevi (2) ujedno tvore spojne kanalne strukture koji omogućavaju strujanje i prinudno hlađenje strujom hladnog zraka iz mlaznica za hlađenje (19) koje su smješteno unutar rečene strukture, i
The antibody for use according to claim 17, wherein, said chemotherapeutic agent is Taxotere® (docetaxel), said anti-angiogenic agent is selected from angiostatin K1-3, Arresten, aaAT, Canstatin, DL-a-Difluoromethyl-ornithine, Endostatin, Fumagillin, Genistein, Minocycline, Staurosporine, Thalidomide, and Tumstatin or said immunomodulatory agent is selected from anti-PD1 antibodies, anti-CTLA-4 antibodies, phosphorothiolate oligodeoxyribonucleotide (1018 ISS), GM-CSF gene vaccines, interleukin-2, interleukin-7 (CYT 99 07), interleukin-12 and interleukin-21. 
Protutijelo za upotrebu u skladu s patentnim zahtjevom 17, naznačeno time, da je navedeno kemoterapijsko sredstvo Taxotere" (docetaxel), navedeno antiangiogeno sredstvom je odabrano između sljedećeg: angiostatin K1- 3, aresten, aaAT, Canstatin, DL-a-difluorometil-ornitin, endostatin, fumagilin, genistein, minociklin, staurosporin, talidomid 1 tumstatin, a navedeno imunomodulacijsko sredstvom odabrano je između sljedećeg: anti-PD1 protutijela, anti-CTLA-4 protutijela, fosforotiolat oligodeoksiribonukleotid (1018 ISS), GM-CSF genska cjepiva, interleukin-2, interleukin-7 (CYT 99 07), interleukin-12 I interleukin-21.
Another permeation enhancer is heat. 
Slijedeće sredstvo za poboljšanje prodiranja je toplina.
In another embodiment, X is H, which can be depicted as formula f: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je X H i ima formulu f:
The process of claim 3, where L is a sulfonic ester group having the formula —OS(O2)—R, where R is —C1-4alkyl or phenyl, and the phenyl group is optionally substituted with —C1-4alkyl, halo or nitro. 
Postupak prema zahtjevu 3, naznačen time da je L sulfonska skupina estera sa formulom -OS(O>)-R, pri čemu je R Craalkil ili fenil, a fenil grupa je dodatno supstituirana s -Cyaalkil, halo ili nitro.
A compound or a pharmaceutically acceptable salt thereof according to claim 1 for use in a method of treating or preventing an AB-related pathology, wherein said AB-related pathology is Down's syndrome, a B-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's Disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu sa zahtjevom 1 naznačen time da je za uporabu u postupku liječenja ili prevencije AB-povezane patologije, pri čemu navedena AB-povezana patologija je Downov sindrom, B-amiloidna angiopatija, cerebralna amiloidna angiopatija, nasljedno cerebralno krvarenje, poremećaj povezan s kognitivnim poremećajem, MCI ("blagi kognitivni poremećaj"), Alzheimerova bolest, gubitak pamćenja, simptomi poremećaja pažnje povezani s Alzheimerovom bolesti, neurodegeneracija povezana s Alzheimerovom bolesti, demencija miješanog vaskularnog podrijetla, demencija degenerativnog porijekla, presenilna demencija, senilna demencija, demencija povezana s Parkinsonovom bolesti, progresivna supranuklearna paraliza i kortikobazalna degeneracija.
A lifting device according to claim 6, wherein the adjustable fixing arrangement enables the suction mount to be pivoted or tilted with respect to the elongate lifting arm. 
Naprava za podizanje prema zahtjevu 3, naznačena time da podesivi pričvrsni sklop (110) omogućava da se vakuumski nosač zakreće ili naginje u odnosu na izduženi podizni krak.
EXAMPLES The following non-limiting examples illustrate the synthesis and properties of the dihydrotetrabenazine compounds of the invention. 
HR P20080677 T3 PRIMJERI Slijedeći ne-limitirajući primjeri ilustriraju sinteze i svojstva dihidrotetrabenazin spojeva izuma.
The PD-1 antibody or the antigen-binding fragment thereof according to any one of claims 1-10, wherein the antibody or the antigen-binding fragment thereof is a chimeric antibody or a fragment thereof. 
PD-1 protutijelo ili njegov fragment koji se veže na antigen sukladno patentnom zahtjevu 1, pri čemu je to protutijelo ili njegov fragment koji se veže na antigen kimerno protutijelo.
paraffins, tetrahydronaphthalene, alkylated naphthalenes and their derivatives, alkylated benzenes and their derivatives, alcohols such as methanol, ethanol, propanol, butanol and cyclohexanol, ketones such as cyclohexanone, strongly polar solvents, such as N-methylpyrrolidone and water. 
parafini, tetrahidronaftalin, alkilirani naftalini i njihovi derivati, alkilirani benzoli i njihovi derivati, alkoholi kao što su metanol, etanol, propanol, butanol i cikloheksanol, ketoni kao što je cikloheksanon, jaka polarna otapala, kao što je N-metilpirolidon i poželjno voda.
The aqueous pharmaceutical suspension according to claim 3, further comprising, by weight/volume (g/100 mL), 0% to 0.50% of an opacifying agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), 0 % do otprilike 0,50 % sredstva za zamućivanje.
The apparatus according to claim 1, wherein the output signal includes handshake data and authentication data, and the apparatus receives additional handshake and authentication data from a further data received from the next apparatus in chain. 
Sustav u skladu s patentnim zahtjevom 1, naznačen time što izlazni signal sadrži podatke o uspostavi veze i podatke o vjerodostojnosti, a uređaj u lancu uređaja prima dodatne podatke o uspostavi veze i podatke o vjerodostojnosti iz dodatnih podataka, primljenih 1z sljedećeg uređaja u lancu.
The pharmaceutical composition of claim 1, wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01 % polysorbate-20, pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, 50 mM citrata.
The method of claim 1, wherein the ratio of total protease to total lipase is about 4:1. 
Oralno farmaceutski spoj za za uporabu sukladno zahtjevu 5, naznačena time što je omjer ukupne proteaze prema ukupnom omjeru lipaze od 4: 1 do 10: 1.
Feature 16 A process according to feature 14 wherein R1 is benzyl and the benzyl group is removed in the presence of trifluoroacetic acid and the compound of Formula IX is converted into a trifluoroacetic acid salt by addition of potassium hydroxide or the addition of sodium hydroxide and water. 
Postupak prema zahtjevu 6, naznačen time, da R' je benzil, a benzilna skupina se odstranjuje u prisutnosti trifluorooctene kiseline, a spoj formule IX se pretvara u trifluorooctenu kiselu sol pomoću dodavanja kalij hidroksida ili pomoću dodavanja natrij hidroksida i vode.
The programmable electrical control device according to claim 1, wherein the entire programmable electrical control device is positioned within the body. 
Programabilni električni upravljački uređaj (10) sukladno bilo kojem zahtjeva 1 do 8, naznačen time da je cijeli programabilni električni upravljački uređaj (12) smješten unutar tijela.
The crystalline form of Febuxostat, according to claim 3, farther characterized by data selected from one or more of the following: an X-ray powder diffraction pattern substantially as depicted in FIG. 
Kristalni oblik febuksostata označen kao Oblik F10, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je za njega dodatno karakteristična difrakcija rendgenskih zraka na prahu sa signalima na 3,3%,
The lozenge of claim 1 wherein step (b) heats the mixture of step (a) to approximately 110-120° C. 
Postupak prema patentnom zahtjevu 41, naznačen time što se smjesa zagrijava do približno 110-120%*C.
Thus Process A may involve taking the known isomers of dihydrotetrabenazine, dehydrating them to form the alkene (II) and then "dehydrating" the alkene (II) using conditions that give the required novel cis dihydrotetrabenazine isomers of the invention. 
Tako Postupak A može obuhvaćati uzimanje poznatih izomera dihidrotetrabenazina, njihovo dehidriranje do alkena (II) i zatim "rehidriranje" alkena (II) uporabom uvjeta koji daju traženi novi cis izomer dihidrotetrabenazina izuma.
or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein: Ring B and the NH-C(=X)-NH moiety are in the trans configuration; 
Spoj koji je odabran - od spojeva s Formulom I: ili stereoizomeri, tautomeri, ili njihove farmaceutski prihvatljive soli ili solvati, naznačen time da: Prsten B i skupina NH-C(=X)-NH su u trans konfiguraciji;
5% to 35% by weight of the dry matter of a non-hydrolysed oat protein isolate or concentrate, 
do 45 masenih % zobenih mekinja, cjelovitog zobenog brašna ili njihovu mješavinu, i
A cell comprising an antibody or an antigen-binding fragment according to any one of claims 1 to 12 or a chimeric molecule according to claim 13, or a chimeric antigen receptor according to claim 14, or a polynucleotide according to claim 15 or 16, in particular a T cell. 
Stanica koja sadrži antitijelo ili antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 12 ili himerna molekula u skladu s patentnim zahtjevom 13, ili himerni receptor antigena u skladu s patentnim zahtjevom 14, ili polinukleotid u skladu s patentnim zahtjevom 15 ili 16, naročito T stanica.
The compound of claim 8, wherein R2 and R3 are connected to form cyclopropyl. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time što su R2 i R3 povezani kako bi tvorili ciklopropil.
The method as in item 6, wherein the pressing against the embossed matrix creates an embossing depth that exceeds the combined thickness of the decorative layer and the transparent wear layer. 
Postupak prema zahtjevu 6, naznačen time da pritisak na reljefnu matricu stvara dubinu utiskivanja koja prelazi kombiniranu debljinu dekorativnog sloja (3) i prozirnog sloja za habanje (5).
The kit of claim 9, wherein when said condition is an ischemic heart condition or cardiac arrhythmia, said administering comprises sublingual, buccal, transdermal, intranasal, or inhalation administration, or when said condition is a hypertensive crisis in an emergency room setting, said administering comprises sublingual, buccal, intranasal, inhalation, or parenteral administration, preferably said parenteral administration is intravenous administration, or when said condition is hypertension before, during, or after surgery, or no-reflow phenomenon following reperfusion, said administering comprises parenteral administration, preferably intravenous administration, or when said condition is a disease associated with decreased skeletal muscle blood flow, said administering comprises sublingual, buccal, transdermal, intranasal, inhalation, or topical administration. 
Komplet prema zahtjevu 9, naznačen time da kada je navedeno stanje ishemijsko stanje srca ili srčana aritmija, navedena primjena je sublingvalna, bukalna, transdermalna, intranazalna, ili inhalacijska primjena, ili kada je navedeno stanje hipertenzivna kriza u sobi za hitne slučajeve, navedena primjena je sublingvalna, bukalna, intranazalna, inhalacijska, ili parenteralna primjena, poželjno navedena parenteralna primjena je intravenozna primjena, ili kada je navedeno stanje hipertenzija prije, za vrijeme, ili nakon operacije, ili fenomen odsutnosti protoka poslije reperfuzije, navedena primjena je parenteralna primjena, poželjno intravenozna primjena, ili kada je navedeno stanje bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, navedena primjena je sublingvalna, bukalna, transdermalna, intranazalna, inhalacijska, ili topikalna primjena.
Compound (I-S) has the following structure: 
Čvrsti oblik HCI soli spoja (I-S):
However, the essentially inactive (-)-a-[11C]dihydrotetrabenazine isomer was almost uniformly distributed in the brain, suggesting that specific binding to DAT and VMAT2 was not occurring. 
Doduše, esencijalno neaktivan (-)-0, -['"C]dihidrotetrabenazin izomer je bio gotovo jednolično raspodijeljen u mozgu, ukazujući da nije došlo do specifičnog vezivanja na DAT i VMAT2.
A process for preparing an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone, which process comprises the steps of: 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 15 ppm.
a replacement of a genomic DNA of a mouse IL-4Ra gene at an endogenous mouse IL-4Ra locus with a human genomic DNA of a human IL-4Ra gene to form a humanized IL-4Ra gene, wherein the genomic DNA of the mouse IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the mouse IL-4Ra gene, and the human genomic DNA of the human IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene, wherein the humanized IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene and exons 6-9 of the mouse IL-4Ra gene, wherein expression of the humanized IL-4Ra gene is under control of the mouse IL-4Ra promoter at the endogenous mouse IL-4Ra locus, 
Postupak dobivanja humaniziranog glodavca, naznačen time što se sastoji u zamjeni genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra. genomskim fragmentom gena za ljudski IL-4Ra kako bi se dobilo gen za humanizirani IL-4Ra. koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ro, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra. sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ra sadrži početni gen ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, gdje je gen za humanizirani IL-4Ro. operativno povezan s regulacijskim elementim glodavačkog IL-4Ra na lokusu za endogeni glodavački IL-4Ra.
The communication apparatus of claim 2, wherein the transmitter is a wireless transmitter adapted to transmit data to the remote computer in a wireless manner. 
Komunikacijski uređaj sukladno zahtjevu 2, naznačen time, što je predajnik bežični predajnik prilagođen za bežični prijenos podatka do udaljenog računala.
Pump the mass to the holding tank. 
Pumpati masu u rezervoar za čuvanje.
In other words, in the equation calculating the amount of the resource of control information, a reduction in the amount of the resource of data signals (i.e., MSCPUSCH-transmission•NSymbPUSCH-retransmission) on retransmission results in a reduction in the amount of the resource of control information, which leads to the degradation of reception quality of control information. 
Postupak prijenosa za prijenos kontrolne informacije u pluralitetu slojeva, postupak sadržeći: određivanje količine resursa kontrolne informacije u pluralitetu slojeva; 1 prijenos kontrolne informacije na temelju količine resursa kontrolne informacije, naznačeno time da je količina resursa Qowso+cwsr kontrolne informacije određena jednadžbom 1: r t
A surface-reacted calcium carbonate obtainable by a process according to any one of claims 1 to 20, wherein the surface is partially reacted with weak acids selected from boric acid, citric acid, sodium dihydrogen citrate, potassium dihydrogen citrate, disodium hydrogen citrate, dipotassium hydrogen citrate, sodium dihydrogen borate, potassium dihydrogen borate, disodium hydrogen borate, dipotassium hydrogen borate and mixtures thereof, the carbonate having a specific BET surface area of more than 50 m2/g, more preferably more than 60 m2/g and most preferably more than 80 m2/g. 
Površinski reaktivni kalcijev karbonat koji je dobiven postupkom prema bilo kojem od zahtjeva 1 do 20, naznačen time da površina djelomično reagira sa slabim kiselinama koje su odabrane od borne kiseline, limunske kiseline, natrijevog dihidrogcn citrata, kalijevog dihidrogen citrata, dinatrijevog hidrogcn citrata, dikalijevog hidrogen citrata, natrijevog dihidrogen borata, kalijevog dihidrogen borata, dinatrijevog hidrogen borata, dikalijevog hidrogen borata i njihovih mješavina, te karbonat ima specifičnu površinu prema BET-u od više od 50 m"/g, još poželjnije više od 60 m/g i najpoželjnije više od 80 m?/g.
DAT days after treatment 
broj dana poslije tretmana
The aqueous pharmaceutical suspension according to claim 2, wherein the pH is about 5.80 to about 7.00 and the particle size is less than about 40 µm for at least about 90% of the fexofenadine zwitterionic dihydrate Form I. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 2, naznačena time što pH je otprilike 5,80 do otprilike 7,00, a veličina čestica je manja od otprilike 40 mm za najmanje otprilike 90 % dvojnoionskog dihidratnog Oblika I feksofenadina.
perhaloalkyl; or -membered heteroaryl ring having up to two heteroatoms selected from O, N and S; is -H, halogen, perhaloalkyl, -CN, -OR5, -SR5, -NHR5, -N(R5)2, -OH, aryl, or heteroaryl, wherein said aryl can be optionally substituted with up to two substituents selected from C1-8alkyl, halogen, perhaloalkyl, and alkoxy, and said heteroaryl can be optionally substituted with up to two substituents selected from halogen and C1-8alkyl; 
Ra je halogen; perhaloalkil; ili 5-člani heteroaril prsten koji ima sve do dva heteroatoma izabrana između O, N i 5; R4 je -H, halogen, perhaloalkil, -CN, -ORs, -SRs, -NHRs, -N(Rs), -OH, aril ili heteroaril, pri čemu navedeni aril može po izbru biti supstituiran sve do sa po dva supstituenda izabrana iz skupine koju čine C, galkil, halogen, perhaloalkil i alkoksi te navedeni heteroaril može po izboru biti supstituiran sve do sa po dva supstituenda izabrana između halogena i Ci .gakil; ili:
A self-extinguishing expandable composition of vinyl aromatic polymers and/or vinyl aromatic copolymers comprising: 
Samougasiva ekspandabilna mješavina vinilaromatskih polimera i/ili vinilaromatskih kopolimera, koja sadrži:
The host cell of claim 14, wherein said cell is a eukaryotic host cell, preferably selected from CHO cell, NS/0 cell, HEK293 cell, HEK293T cell, plant cell, or fungi, preferably yeast. 
Stanica domaćin prema patentnom zahtjevu 13, pri čemu je navedena stanica eukariotska stanica domaćin, poželjno izabrana od CHO stanice, NS/0 stanice, HEK293 stanice, HEK293T stanice, biljne stanice ili gljive, poželjno kvasca.
In particular, they are suitable for use in the treatment of autoimmune disorders, inflammatory disorders and/or in preventing or reducing the risk of graft rejection in transplantation. 
Izolirano protutijelo prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da se upotrebljava za liječenje autoimunih poremećaja i/ili upalnih poremećaja.
Isomer B, which is believed to have the 2 S,3 S,11b R configuration, was characterized by 1H-NMR, 13C-NMR, IR, mass spectrometry, chiral HPLC, ORD and X-ray crystallography. 
Izomer B, za kojeg se smatra da ima 28,3S,11bR konfiguraciju je okarakteriziran pomoću 'H-NMR, '*C-NMR, IR, masene spektrometrije, hiralne HPLC, ORD 1 kristalografije X-zrakama.
After 16 h, EtOH (100 mL) followed by 50% aqueous hydroxylamine (6.43 mL, 100 mmol) was added and stirred at 80° C. for 2 h. 
Poslije 16 sati, dodan je EtOH (100 mL) i zatim i 50% vodena otopina hidroksilamina (6.43 mL, 100 mmol) i miješanje je izvršeno na 80*C u trajanju od 2 sata.
The bi-specific antibody according to Claim 1, wherein the VL-PDGFR and VH-PDGFR domains comprise the amino acid sequences as shown in SEQ ID NOs: 46 and 48, respectively. 
Bispecifično protutijelo u skladu s patentnim zahtjevom 1, pri čemu VL-PDGFR i VH-PDGFR domene obuhvaćaju sljedove aminokiselina prikazane redom u sljedovima identifikacijskih brojeva: 46 i 48.
means (702-0) for encoding the service data having the at least one baseband header by a Low Density Parity Check, LDPC, scheme; 
Kabelski predajnik iz patentnog zahtjeva 5, nadalje obuhvaća: sredstvo (209) za nasumično kodiranje servisnih podataka koji imaju najmanje jedno zaglavlje osnovnog frekvencijskog pojasa.